검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pirtobrutinib (Pirtobrutinib) SWOG Cancer Research Network·Chronic Lymphocytic Leukemia ORR 66.4%·t½ 20 h |
|---|---|
Overview Program | Pirtobrutinib |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | Chronic Lymphocytic Leukemia |
Overview Indication | Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits B-cell receptor signaling |
MoA Biomarker | biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with rel |
PK/PD Half-life | 20 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia are driven by B cell dysfunction |
Clinical Primary efficacy | ORR 66.4% |
Clinical ORR | 66.4% |
Clinical PFS | 13.96 |
Clinical OS | 29.67 |
Clinical Result source | ClinicalTrials.gov NCT04666038 |
Clinical Data Tier / Score | A · 73 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pirtobrutinib (Pirtobrutinib) SWOG Cancer Research Network·Chronic Lymphocytic Leukemia ORR 66.4%·t½ 20 h |
|---|---|
Overview Program | Pirtobrutinib |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | Chronic Lymphocytic Leukemia |
Overview Indication | Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits B-cell receptor signaling |
MoA Biomarker | biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with rel |
PK/PD Half-life | 20 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia are driven by B cell dysfunction |
Clinical Primary efficacy | ORR 66.4% |
Clinical ORR | 66.4% |
Clinical PFS | 13.96 |
Clinical OS | 29.67 |
Clinical Result source | ClinicalTrials.gov NCT04666038 |
Clinical Data Tier / Score | A · 73 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교